返回Google圖書搜尋

Combined Modality Treatment of Adductor Spasmodic Dysphonia

出版	University of Florida, 2007
URL	http://books.google.com.hk/books?id=N4iWnQAACAAJ&hl=&source=gbs_api

註釋ABSTRACT: Adductor type spasmodic dysphonia (ADSD) is a neurogenic voice disorder which directly affects muscles within the human larynx that are responsible for the production of voice. The hallmark characteristic of this disorder is the presence of irregular and uncontrollable spasms within these muscles, resulting in erratic disruption of normal voicing. The purpose of the present study was to determine the effect of voice therapy following botulinum toxin type A (BTX-A) injections for ADSD on duration of injection benefit, perceived vocal quality of life, and various acoustic measures of vocal instability. The study also sought to compare these effects with those observed in participants who had only received BTX-A injections, and those who had received BTX-A injections followed by a "sham" voice therapy. Thirty-one individuals with ADSD participated in this study. None of the participants had ever had prior BTX-A injections. All participants had elected to receive BTX-A injections for ADSD. Following enrollment, one-third received no further intervention following injection, one-third received a standard five-week course of voice therapy following injection, and one-third received a five week course of sham voice therapy following injection. Variables of interest were duration of injection benefit, quality of life as indicated by standard scores from the Voice-Related Quality of Life (V-RQOL) battery, as well as acoustic measures of vocal instability